mRNA Startup's $34M Round: What It Means for Biotech

Jan de Vries · 2026-11-09

SRTD Biotech, a German startup based in Jülich, just closed an oversubscribed seed round worth about $34 million (€31.5 million). That's a big vote of confidence for a company trying to make mRNA therapies more precise. Instead of hitting every cell in sight, their tech aims to target only the diseased ones. The round was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund as co-leads. Lilly Ventures, HTGF, and Freiburg-based family office Anobis Asset also joined in. Not a bad lineup for a seed stage. ### Why precision mRNA matters mRNA therapeutics have huge potential, but one major challenge is making sure they only affect the cells you want. SRTD's approach uses intracellular RNA disease markers to activate mRNA expression exclusively within target cells. In plain English: the therapy only turns on where it's needed, leaving healthy tissue alone. They call these selectively expressed RNA (seRNA) constructs. The idea is to overcome the limitations of non-selective mRNA expression and the constraints of targeting cell-surface proteins. If it works, it could mean safer, more effective treatments for a range of diseases. ### A platform play SRTD isn't just one trick. They've built three technology platforms: - Proprietary seRNA technology - A novel fusogenic lipid nanoparticle (LNP) delivery platform that can reach the liver, lungs, brain, and other organs - A synthetic biology platform with bioinformatics and AI-driven RNA design Together, these give them an end-to-end solution for generating differentiated RNA therapies across many therapeutic areas. ### New leadership to scale up With the funding in place, SRTD has appointed Matthias Alder as CEO. He's held senior roles (CEO, COO, CBO) at publicly traded biotech companies in the US and Europe. "The proceeds will enable SRTD to advance Bernd's vision of delivering safe, effective, and differentiated RNA therapeutics to patients whose diseases remain inadequately addressed by current therapies," Alder said. Dr. Heinz Koeppl joins as CTO and founder of the synthetic biology platform. He's also a professor at TU Darmstadt and director of its Centre for Synthetic Biology. Dr. Jens Hennecke comes on board as CBO to drive business development and strategy. > "SRTD Biotech shows how cutting-edge research from North Rhine-Westphalia can open up new ways to treat many diseases with significant unmet medical needs. Bringing innovations like these from research into medical practice takes capital. With our investment, we are helping a highly innovative company develop a promising new technology in NRW and scale it internationally from here." – Johanna Antonie Tjaden-Schulte, Member of NRW.BANK's Managing Board. ### What this means for the ecosystem For US investors and founders watching Europe, this deal signals that deep tech biotech can still attract serious capital. The syndicate includes both strategic and financial investors, which is a good sign for the company's long-term potential. And the fact that it's oversubscribed? That means demand was higher than the round size – a rare feat in today's funding environment. SRTD plans to use the funds to advance its pipeline and platform, aiming to bring safer, more effective RNA therapies to patients. If they succeed, it could reshape how we think about mRNA medicines – not just as a vaccine technology, but as a precise therapeutic tool. For now, all eyes are on Jülich to see what this team does next.